Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.
The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial.
Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.79 Decreased by -6.69% | -0.78 Decreased by -1.22% |
| Feb 28, 24 | -0.79 Increased by +10.23% | -0.66 Decreased by -19.70% |
| Nov 8, 23 | -0.71 Increased by +13.41% | -0.77 Increased by +7.79% |
| Aug 8, 23 | -0.66 Increased by +28.26% | -0.80 Increased by +17.50% |
| May 9, 23 | -0.74 Decreased by -4.23% | -0.85 Increased by +12.94% |
| Feb 28, 23 | -0.88 Decreased by -7.32% | -0.89 Increased by +1.12% |
| Nov 8, 22 | -0.82 Decreased by -20.59% | -0.93 Increased by +11.83% |
| Aug 9, 22 | -0.92 Decreased by -31.43% | -0.75 Decreased by -22.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 2.82 M Increased by +13.54% | -52.36 M Decreased by -23.87% | Decreased by -1.86 K% Decreased by -9.10% |
| Jun 30, 23 | 2.32 M Increased by +6.34% | -47.02 M Decreased by -5.75% | Decreased by -2.03 K% Increased by +0.56% |
| Mar 31, 23 | 2.23 M Increased by +24.40% | -47.19 M Decreased by -38.76% | Decreased by -2.11 K% Decreased by -11.54% |
| Dec 31, 22 | 2.77 M Increased by +49.51% | -47.72 M Decreased by -23.85% | Decreased by -1.72 K% Increased by +17.17% |
| Sep 30, 22 | 2.48 M Increased by +14.75% | -42.27 M Decreased by -44.39% | Decreased by -1.70 K% Decreased by -25.83% |
| Jun 30, 22 | 2.18 M Decreased by -16.46% | -44.47 M Decreased by -68.75% | Decreased by -2.04 K% Decreased by -101.99% |
| Mar 31, 22 | 1.79 M Decreased by -33.62% | -34.01 M Decreased by -42.64% | Decreased by -1.89 K% Decreased by -114.87% |
| Dec 31, 21 | 1.85 M Decreased by -13.54% | -38.53 M Decreased by -136.74% | Decreased by -2.08 K% Decreased by -173.81% |